Skip to main content
OpenTrials
Completed

NCT Number: NCT05387941

Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants

Background and study aims

When an infant is born premature, the blood vessels in the eyes have not developed fully on the retina, and can start to grow incorrectly and result in blindness. To prevent this from happening, premature infants are often screened, and treated with laser or injections into the eye to prevent retinal detachment. A new treatment strategy with steroid eye drops have been found to prevent serious blood vessel growth. The treatment is commonly used in older children and adults to treat different inflammatory conditions, but how the drop is absorbed in premature infants and if there is any risk of side-effects is poorly investigated. The aim of this study is to document how the steroid drop is absorbed and excreted in premature infants and to study if there is a risk of any side effects.

Who can participate?

Premature infants born before gestational age week 30, that undergo eye-screening at Sahlgrenska University Hospital in Gothenburg and Skånes University Hospital in Malmö and Lund or at Helsingborg Hospital, in the need for steroid eye-drop treatment against pathological vessels. It is not possible to participate if the infant has received systemic steroid treatment 2 weeks prior to the eye-drop treatment, or has an ongoing ocular infection.

What does the study involve?

The study involves blood and saliva samples according to a specific protocol designed to be able to learn about the uptake and breakdown of the steroid in premature infants. Measurements of blood pressure, growth and a few urine samples will also be collected during the treatment period usually lasting for some weeks.

At 2.5 and 5 years of age, visual acuity, refractive errors and retinal thickness measurements will be noted.

What are the possible benefits and risks of participating?

The infant will receive steroid eye-drops that have been noted to heavily reduce the number of infants that develop retinal changes that require injections or laser treatment.

The blood samples have been reduced to an absolute minimum in volume and numbers, but will entail some extra samplings from the infant.

The infant will be rigorously checked with regard to any possible side effects from the steroid treatment. Possible but unlikely side effects from the low dose in eye drops are; elevated blood pressure, retarded growth, lowered endogenous steroid production during the eye-drop treatment, increase in blood glucose, and an increase in intra-ocular pressure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 30 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Skåne University Hospital, Lund, Skåne County, Sweden

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants screened for retinopathy of prematurity (ROP) at Sahlgrenska University Hospital in Gothenburg, at Skåne University Hospital in Malmö and Lund and at Helsingborg Hospital.
  • zone I stage 1 or 2 ROP without plus disease, posterior zone II stage 2 ROP without plus disease, or zone II stage 3 ROP without plus disease. ROP needs to be documented by digital widefield photography and classification confirmed by two ophthalmologist.

Exclusion criteria

  • ocular infection
  • systemic steroid treatment within two weeks before the start of drop treatment

Treatment and study plan

Dexamethasone Ophthalmic

Drug

one drop daily in each eye with retinopathy of prematurity of a predefined stage.

Other names: dexafree

Primary outcomes

  1. Pharmacokinetics: half-life of plasma concentrations of dexamethasone during treatment with dexamethasone eye drops measured with mass spectrometry.

    Time frame: up to 14 weeks

    Half-life of dexamethasone- t½, hours

  2. Pharmacokinetics: maximum plasma concentration of dexamethasone during treatment with dexamethasone eye drops measured with mass spectrometry.

    Time frame: up to 14 weeks

    Maximum plasma concentration- Cmax, nmol/L

  3. Pharmacokinetics: saliva koncentrations of dexamethasone during treatment with dexamethasone eye drops.

    Time frame: up to 14 weeks

    Half-life of dexamethasone- t½, hours

  4. Pharmacokinetics: saliva koncentrations of dexamethasone during treatment with dexamethasone eye drops measured with mass spectrometry.

    Time frame: up to 14 weeks

    Maximum saliva concentration- Cmax, nmol/L

  5. Pharmacokinetics: time to reach maximum plasma concentration of dexamethasone during treatment with dexamethasone eye drops measured with mass spectrometry.

    Time frame: up to 14 weeks

    tmax, hours

  6. Pharmacokinetics: time to reach maximum saliva concentrations of dexamethasone during treatment with dexamethasone eye drops measured with mass spectrometry.

    Time frame: up to 14 weeks

    tmax, hours

  7. Pharmacokinetics: area under the concentration-time curve for plasma dexamethasone from time point 0 to time t of the last measured concentration above the limit of quantification time.

    Time frame: up to 14 weeks

    AUC0-t, nmol.h/L

  8. Pharmacokinetics: area under the concentration-time curve for saliva dexamethasone from time point 0 to time t of the last measured concentration above the limit of quantification time.

    Time frame: up to 14 weeks

    AUC0-t, nmol.h/L

  9. Pharmacokinetics: area under the concentration-time curve for plasma dexamethasone from time point 0 to infinity;

    Time frame: up to 14 weeks

    AUC0-∞, nmol.h/L

  10. Pharmacokinetics: area under the concentration-time curve for saliva dexamethasone from time point 0 to infinity;

    Time frame: up to 14 weeks

    AUC0-∞, nmol.h/L

  11. Pharmacokinetics: apparent total body clearance

    Time frame: up to 14 weeks

    CL/F, L/h

  12. Pharmacokinetics: apparent volume of distribution

    Time frame: up to 14 weeks

    Vz/F, L

  13. Safety: serum concentrations of endogenous corticosteroids before, during and after treatment with dexamethasone eye drops measured with mass spectrometry.

    Time frame: up to 14 weeks

    Endogenous levels of corticosteroids, nmol/L

  14. Safety: saliva concentrations of endogenous corticosteroids before, during and after treatment with dexamethasone eye drops.

    Time frame: up to 14 weeks

    Endogenous levels of corticosteroids, nmol/L

Secondary outcomes

  1. To describe if dexamethasone eye drops delay the intervention for type 1 ROP in cases without regression by calculating the time from detection of type 2 ROP to type 1 ROP

    Time frame: Up to 14 weeks

    Time from detection of type 2 ROP to type 1 ROP, days

  2. To describe if dexamethasone eye drop treatment before intervention for type 1 ROP reduces the number of recurrences after the intervention.

    Time frame: Up to 14 weeks

    recurrences after laser/anti-VEGF treatment, percentage

  3. To find out if retinal morphology measured with optical coherence tomography is affected by dexamethasone eye drops at 2.5 years of age.

    Time frame: after 2.5 years

    Retinal thickness, micrometers

  4. To find out if retinal morphology measured with optical coherence tomography is affected by dexamethasone eye drops at 5 years of age.

    Time frame: after 5 years

    Retinal thickness, micrometers

  5. To find out if dexamethasone eye drops affect visual acuity at 2.5 years of age

    Time frame: after 2.5 years

    Visual acuity according to Snellen, fraction

  6. To find out if dexamethasone eye drops affect refractive errors at 2.5 years of age

    Time frame: after 2.5 years

    Refractive power, diopters

  7. To find out if dexamethasone eye drops affect visual acuity at 5 years of age

    Time frame: after 5 years

    Visual acuity according to Snellen, fraction

  8. To find out if dexamethasone eye drops affect refractive errors at 5 years of age

    Time frame: after 5 years

    refractive power, diopters

Sponsors and collaborators

Lead sponsor

Region Skane

Other

Registry information

Official study title

Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants With Retinopathy of Prematurity- a Feasibility Study

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
May 24, 2022
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.